UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1607
    +0.0010 (+0.09%)
     
  • GBP/USD

    1.3834
    -0.0060 (-0.43%)
     
  • BTC-GBP

    35,925.86
    +647.58 (+1.84%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • DOW

    31,496.30
    +572.16 (+1.85%)
     
  • CRUDE OIL

    66.28
    +2.45 (+3.84%)
     
  • GOLD FUTURES

    1,698.20
    -2.50 (-0.15%)
     
  • NIKKEI 225

    28,864.32
    -65.78 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.51 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Global Autoimmune Disease Therapeutics Market (2021 to 2025) - Size & Forecast with Impact Analysis of COVID-19

Research and Markets
·6-min read

Dublin, Feb. 23, 2021 (GLOBE NEWSWIRE) -- The "Global Autoimmune Disease Therapeutics Market: Size & Forecast with Impact Analysis of COVID-19 (2021-2025)" report has been added to ResearchAndMarkets.com's offering.

This report provides an in depth analysis of the global autoimmune disease therapeutics market by value, by drug class, by indication, by region, etc. The report provides a regional analysis of the autoimmune disease therapeutics market, including the following regions: North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. The report also provides a detailed analysis of the COVID-19 impact on the autoimmune disease therapeutics market.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global autoimmune disease therapeutics market has also been forecasted for the period 2021-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.

The global autoimmune disease therapeutics market is fragmented with many major market players operating worldwide. The key players of the autoimmune disease therapeutics market are Roche Holding AG, Pfizer Inc., Johnson & Johnson, and Abbott Laboratories are also profiled with their financial information and respective business strategies.

Country Coverage

  • North America

  • Europe

  • Asia Pacific

  • Middle East & Africa

  • Latin America

An autoimmune disease is a condition in which the body's immune system attacks and destroys healthy cells and tissues in the body by mistake. In other words, autoimmune disease arises when the immune system fails to distinguish between the body's own cells and foreign cells. These diseases can affect any part of the body. Autoimmune disease therapeutics is a form of treatment to calm the overactive immune response, to limit tissue damage, and to reduce pain and inflammation. Treatment can also help in relieving symptoms like pain, swelling, and skin rashes.

There are a lot of therapeutic alternatives available, but no option has a perfect safety profile. In fact, while some treatments have been effective in treating certain autoimmune disorders, no treatment is effective for all autoimmune diseases.

The autoimmune disease therapeutics market can be segmented on the basis of drug class (Immunosuppressant's, Anti-inflammatory Drug, Interferons, NSAIDs, Antihyperglycemics, and Others); indication (Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease, Type 1 Diabetes, Psoriasis, and Others); and distribution channel (Hospital & Clinics, Pharmacies, Drug Stores, Online Stores, and Others).

The global autoimmune disease therapeutics market has increased significantly during the years 2018-2020 and projections are made that the market would rise in the next four years i.e. 2021-2025 tremendously. The autoimmune disease therapeutics market is expected to increase due to rapid urbanization, escalating healthcare spending, rising prevalence of autoimmune diseases, favorable government initiatives, etc. Yet the market faces some challenges such as high cost involved, lack of approved treatment for IPF (Idiopathic Pulmonary Fibrosis), etc.

Key Topics Covered:

1. Executive Summary

2. Introduction
2.1 Autoimmune Disease: An Overview
2.1.1 Most Common Autoimmune Diseases
2.1.2 Areas Affected by Autoimmune Diseases
2.1.3 Common Autoimmune Disease Symptoms
2.2 Autoimmune Disease Therapeutics: An Overview
2.2.1 Evolution of Autoimmune Disease Treatment Depending on the Severity of the Disease
2.3 Autoimmune Disease Therapeutics Segmentation: An Overview
2.3.1 Autoimmune Disease Therapeutics Segmentation by Drug Class
2.3.2 Autoimmune Disease Therapeutics Segmentation by Indication
2.3.3 Autoimmune Disease Therapeutics Segmentation by Distribution Channel

3. Global Market Analysis
3.1 Global Autoimmune Disease Therapeutics Market: An Analysis
3.1.1 Global Autoimmune Disease Therapeutics Market by Value
3.1.2 Global Autoimmune Disease Therapeutics Market by Drug Class (Anti-inflammatory, Interferons, NSAIDs, Antihyperglycemics and Others)
3.1.3 Global Autoimmune Disease Therapeutics Market by Indication (Rheumatoid Arthritis, Multiple Sclerosis, Inflammatory Bowel Disease, Type 1 Diabetes and Other Indications)
3.1.4 Global Autoimmune Disease Therapeutics Market by Region (North America, Europe, Asia Pacific, Middle East & Africa and Latin America)
3.2 Global Autoimmune Disease Therapeutics Market: Drug Class Analysis
3.2.1 Global Anti-Inflammatory Autoimmune Disease Therapeutics Market by Value
3.2.2 Global Interferons Autoimmune Disease Therapeutics Market by Value
3.2.3 Global NSAIDs Autoimmune Diseases Therapeutics Market by Value
3.2.4 Global Antihyperglycemics Autoimmune Disease Therapeutics Market by Value
3.2.5 Global Others Autoimmune Disease Therapeutics Market by Value
3.3 Global Autoimmune Disease Therapeutics Market: Indication Analysis
3.3.1 Global Rheumatoid Arthritis Therapeutics Market by Value
3.3.2 Global Type 1 Diabetes Therapeutics Market by Value
3.3.3 Global Multiple Sclerosis Therapeutics Market by Value
3.3.4 Global Inflammatory Bowel Disease Therapeutics Market by Value
3.3.5 Global Other Indications Therapeutics Market by Value

4. Regional Market Analysis
4.1 North America Autoimmune Disease Therapeutics Market: An Analysis
4.1.1 North America Autoimmune Disease Therapeutics Market by Value
4.2 Europe Autoimmune Disease Therapeutics Market: An Analysis
4.2.1 Europe Autoimmune Disease Therapeutics Market by Value
4.3 Asia Pacific Autoimmune Disease Therapeutics Market: An Analysis
4.3.1 Asia Pacific Autoimmune Disease Therapeutics Market by Value
4.4 Middle East & Africa Autoimmune Disease Therapeutics Market: An Analysis
4.4.1 Middle East & Africa Autoimmune Disease Therapeutics Market by Value
4.5 Latin America Autoimmune Disease Therapeutics Market: An Analysis
4.5.1 Latin America Autoimmune Disease Therapeutics Market by Value

5. Impact of COVID-19
5.1 Impact of COVID-19
5.1.1 Impact of COVID-19 on Healthcare Sector
5.1.2 Impact of COVID-19 on Autoimmune Disease Therapeutics

6. Market Dynamics
6.1 Growth Driver
6.1.1 Rapid Urbanization
6.1.2 Escalating Healthcare Spending
6.1.3 Rising Prevalence of Autoimmune Diseases
6.1.4 Favorable Government Initiatives
6.2 Challenges
6.2.1 High Cost Involved
6.2.2 Lack of Approved Treatment for IPF (Idiopathic Pulmonary Fibrosis)
6.3 Market Trends
6.3.1 Innovations in the Treatment of Autoimmune Diseases
6.3.2 Growing Adoption of JAK Inhibitors for the Treatment of Autoimmune Diseases
6.3.3 Increasing Awareness among Patients towards the Autoimmune Diseases and Therapeutic Treatments

7. Competitive Landscape
7.1 Global Autoimmune Disease Therapeutics Market Players: A Financial Comparison
7.2 Global Autoimmune Disease Therapeutics Market Players by Development of Drugs for IMIDs Targeting JAK

8. Company Profiles
8.1 Roche Holding AG
8.1.1 Business Overview
8.1.2 Financial Overview
8.1.3 Business Strategy
8.2 Pfizer Inc.
8.2.1 Business Overview
8.2.2 Financial Overview
8.2.3 Business Strategy
8.3 Johnson & Johnson
8.3.1 Business Overview
8.3.2 Financial Overview
8.3.3 Business Strategy
8.4 Abbott Laboratories
8.4.1 Business Overview
8.4.2 Financial Overview
8.4.3 Business Strategy

For more information about this report visit https://www.researchandmarkets.com/r/bb1g5v

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900